The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b and n are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.

##STR00001##

The present invention provides a compound that has an inhibitory effect on DYRK and that is represented by general formula (I):

##STR00001##

wherein Q, R.sup.1, R.sup.2 and R.sup.3 are as defined in the description.

The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R.sup.1, R.sup.2 and R.sup.3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.

##STR00001##

The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R.sup.1, R.sup.2 and R.sup.3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.

##STR00001##

A compound of Formula (I) is provided: (I) where the variables are defined herein.

##STR00001##

Provided are a fused tricyclic compound having the structure shown in formula (I), a pharmaceutical composition thereof, and a use thereof. The fused tricyclic compound serves as a selective inhibitor of KRAS mutation, and has high activity, good selectivity. and reduced toxic side effects.

##STR00001##

The present invention provides compounds of formula (I) wherein X is O, S or NR.sup.10, wherein R.sup.10 is H, C.sub.1-30-alkyl, substituted C.sub.1-30-alkyl, C.sub.2-30-alkenyl, substituted C.sub.2-30-alkenyl, C.sub.2-30-alkynyl, substituted C.sub.2-30-alkynyl or C(0)-OR, R.sup.1 and R.sup.11 are independently from each other selected from the group consisting of C.sub.1-30-alkyl, substituted C.sub.1-30-alkyl, C.sub.2-30-alkenyl, substituted C.sub.2-30-alkenyl, C.sub.2-30-alkynyl, substituted C.sub.2-30-alkynyl, C.sub.5-8-cycloalkyl, substituted C.sub.5-8-cycloalkyl, C.sub.5-8-cycloalkenyl, and substituted C.sub.5-8-cycloalkenyl, and an electronic device comprising the compounds as semiconducting material.

##STR00001##

The present invention provides compounds of formula (I) wherein X is O, S or NR.sup.10, wherein R.sup.10 is H, C.sub.1-30-alkyl, substituted C.sub.1-30-alkyl, C.sub.2-30-alkenyl, substituted C.sub.2-30-alkenyl, C.sub.2-30-alkynyl, substituted C.sub.2-30-alkynyl or C(0)-OR, R.sup.1 and R.sup.11 are independently from each other selected from the group consisting of C.sub.1-30-alkyl, substituted C.sub.1-30-alkyl, C.sub.2-30-alkenyl, substituted C.sub.2-30-alkenyl, C.sub.2-30-alkynyl, substituted C.sub.2-30-alkynyl, C.sub.5-8-cycloalkyl, substituted C.sub.5-8-cycloalkyl, C.sub.5-8-cycloalkenyl, and substituted C.sub.5-8-cycloalkenyl, and an electronic device comprising the compounds as semiconducting material.

##STR00001##

A condensed cyclic compound represented by Formula 1 and an organic light-emitting apparatus including the same.

##STR00001##

A condensed cyclic compound represented by Formula 1 and an organic light-emitting apparatus including the same.

##STR00001##